Jesus D - Search Results

1

Systemic Lupus Erythematosus Disease Activity Score Remission and Low Disease Activity States Discriminate Drug From Placebo and Better Health-Related Quality of Life.

Jesus D, Henriques C, Matos A, Doria A, Inês LS. Jesus D, et al. Arthritis Care Res (Hoboken). 2024 Jun;76(6):788-795. doi: 10.1002/acr.25305. Epub 2024 Feb 29. Arthritis Care Res (Hoboken). 2024. PMID: 38258369 Clinical Trial.

2

Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register.

Sousa S, Gonçalves MJ, Inês LS, Eugénio G, Jesus D, Fernandes S, Terroso G, Romão VC, Cerqueira M, Raposo A, Couto M, Nero P, Sequeira G, Nóvoa T, Melo Gomes JA, da Silva JC, Costa L, Macieira C, Silva C, Silva JA, Canhão H, Santos MJ. Sousa S, et al. Among authors: jesus d. Rheumatol Int. 2016 Jul;36(7):955-60. doi: 10.1007/s00296-016-3450-2. Epub 2016 Mar 15. Rheumatol Int. 2016. PMID: 26979603

3

Central nervous system vasculitis in systemic lupus erythematosus: a case series report in a tertiary referral centre.

Rodrigues M, Galego O, Costa C, Jesus D, Carvalho P, Santiago M, Malcata A, Inês L. Rodrigues M, et al. Among authors: jesus d. Lupus. 2017 Nov;26(13):1440-1447. doi: 10.1177/0961203317694259. Epub 2017 Feb 26. Lupus. 2017. PMID: 28420057

4

Risk of damage and mortality in SLE patients fulfilling the ACR or only the SLICC classification criteria. A 10-year, inception cohort study.

Inês L, Rodrigues M, Jesus D, Fonseca FP, Silva JAP. Inês L, et al. Among authors: jesus d. Lupus. 2018 Apr;27(4):556-563. doi: 10.1177/0961203317731534. Epub 2017 Sep 21. Lupus. 2018. PMID: 28933234

5

Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.

Jesus D, Rodrigues M, da Silva JAP, Inês L. Jesus D, et al. Lupus. 2018 Jul;27(8):1358-1362. doi: 10.1177/0961203318758508. Epub 2018 Feb 15. Lupus. 2018. PMID: 29448882

6

Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.

Jesus D, Matos A, Henriques C, Zen M, Larosa M, Iaccarino L, Da Silva JAP, Doria A, Inês LS. Jesus D, et al. Ann Rheum Dis. 2019 Mar;78(3):365-371. doi: 10.1136/annrheumdis-2018-214502. Epub 2019 Jan 9. Ann Rheum Dis. 2019. PMID: 30626657

7

IL-12 and IL-23/Th17 axis in systemic lupus erythematosus.

Larosa M, Zen M, Gatto M, Jesus D, Zanatta E, Iaccarino L, Inês L, Doria A. Larosa M, et al. Among authors: jesus d. Exp Biol Med (Maywood). 2019 Jan;244(1):42-51. doi: 10.1177/1535370218824547. Epub 2019 Jan 21. Exp Biol Med (Maywood). 2019. PMID: 30664357 Free PMC article. Review.

8

Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients.

Jesus D, Rodrigues M, Matos A, Henriques C, Pereira da Silva JA, Inês LS. Jesus D, et al. Lupus. 2019 Apr;28(5):607-612. doi: 10.1177/0961203319836717. Epub 2019 Mar 21. Lupus. 2019. PMID: 30895904

9

Response to: 'Assessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort', by Hassan et al.

Jesus D, Zen M, Doria A, Inês LS. Jesus D, et al. Ann Rheum Dis. 2020 May;79(5):e52. doi: 10.1136/annrheumdis-2019-215430. Epub 2019 Apr 25. Ann Rheum Dis. 2020. PMID: 31023656 No abstract available.

10

Response to: 'SLE-DAS: ready for routine use' by Mathew et al.

Jesus D, Matos A, Henriques C, Zen M, Doria A, Inês LS. Jesus D, et al. Ann Rheum Dis. 2020 Sep;79(9):e117. doi: 10.1136/annrheumdis-2019-215794. Epub 2019 Jun 14. Ann Rheum Dis. 2020. PMID: 31201172 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

223 results

Search Page

Filters